Clinical Trial Update: Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss

View source ↗

Summary

A completed clinical trial evaluated alendronate (Fosamax) for preventing bone loss in perimenopausal women.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteopenia
• Osteoporosis

Drugs mentioned

• FOSAMAX (ALENDRONATE SODIUM)

Snippet

Sponsor: University of California, San Francisco | Conditions: Perimenopausal Bone Loss | Status: COMPLETED